The potential therapeutic applications of NPY receptor agonists Diego, CA, USA and antagonists have stimulated an intensive search for non- 6 Present address: Berlex Biosciences, 15049 San Pablo Ave, Richmond, peptide ligands (Grundemar and Hankanson, 1994) . Recently, CA 94804, USA a potent and selective non-peptide Y1 antagonist, BIBP3226, 2 To whom correspondence should be addressed has been discovered (Figure 1b; Rudolf et al., 1994) .
To study the ligand-receptor interactions between the Y1 Neuropeptide Y (NPY) receptors belong to the G-proteinreceptor and BIBP3226 Y1 as well as NPY, we have built a coupled receptor (GPCR) superfamily and mediate several 3-D model for the human Y1 receptor. Ligand docking studies physiological responses, such as blood pressure, food intake, were carried out for these ligands using this receptor model. sedation and memory retention. To understand the interMutagenesis data for the Y1 receptor were used to locate the actions between the NPY Y1 receptor subtype and its agonist and antagonist binding sites and were compared with ligands, computer modeling was applied to the natural corresponding data from other GPCRs to elucidate common peptide agonist, NPY and a small molecule antagonist, features in the binding model. The main questions that we BIBP3226. An agonist and antagonist binding domain was addressed in this study are (i) what are the amino acid residues elucidated using mutagenesis data for the Y1 receptor as of the Y1 receptor that may interact with these ligands?, (ii) well as for other GPCR families. The agonist and antagonist are the predicted agonist and antagonist binding sites consistent ligands which were investigated appear to share common with experimental data? and (iii) what are the similarities and residues for their interaction within the transmembrane differences between the agonist and antagonist binding sites regions of the Y1 receptor structure, including Gln120, in the human Y1 receptor?
Asn283 and His306. This is in contrast to findings with tachykinin receptors where the binding domains of the non-peptide antagonists have very little in common with
Computational methods the binding domains of the agonist, substance-P. In addition,
Building a 3-D model of the TM regions of the human a hydrogen bond between the hydroxyl group of Tyr36 of Y1 receptor NPY and the side chain of Gln219, an interaction that is
Because no high resolution crystal structure is available for absent in the model complex between Y1 and the antagonist the GPCR superfamily, modeling the 3-D structure of GPCRs BIBP3226, is proposed as one of the potential interactions has been an active area of research in recent years. These necessary for receptor activation.
studies can be summarized in three fundamentally different Keywords: agonist/antagonist/model/mutagenesis/neuropepapproaches. The first approach involves homology modeling tide using the structure of bacteriorhodopsin (BR; Henderson et al., 1990) as a template, assuming that the backbone structure for the GPCR superfamily can be modeled using the BR structure.
Introduction
Studies using this strategy have been reported for many GPCRs (Cronet et al., 1993; Oliveira et al., 1993) , including Neuropeptide Y (NPY), pancreatic polypeptide (PP) and peptide YY (PYY) are 36 amino acid C-terminal amidated β 2 -adrenergic (Trumpp-Kallmeyer et al., 1992) , 5-HT 1A (Trumpp-Kallmeyer et al., 1992) , dopamine D 2 (Livingstone neuropeptides (Figure 1a ). It is believed that these peptides adopt a common hairpin-like tertiary structure, as observed Teeter et al., 1994) , angiotensin II type 1 (Joseph et al., 1995; Underwood et al., 1995; Yamano et al., 1995 ) the X-ray structure of avian PP (Blundell and Wood, 1981) . This structure includes a proline helix for residues 1-8, a turn and other peptide receptors (Grotainger et al., 1991) . Valuable insight into an understanding of the possible structure of for residues 9-14, a helix for residues 15-32 and a C-terminal tail for residues 33-36. The same overall structure was also GPCRs has been obtained from these studies. The second approach of GPCR modeling is to build a observed in the solution NMR of PP (Li et al., 1992) and NPY (Darbon et al., 1992) , although NPY appears to be more receptor model without using the BR structure as a template. This is based on the consideration that the sequence homology flexible than PP in solution. Fig. 1 . Schematic representation of (a) the secondary structure of NPY and (b) the structure of BIBP3226 (adapted from Grundemar et al., 1993) . The key residues of NPY for Y1 receptor binding are highlighted. The C-terminal Tyr36 is amidated.
between GPCRs and BR is extremely low and GPCRs adopt slightly different structures. Indeed, a clearly different helical arrangement has been observed between the GPCR rhodopsin (Schertler et al., 1993; Unger and Schertler, 1995) and BR. The periodicity of amino acid substitution among GPCRs was first used to identify TM helices in GPCR models (Donnelly et al., 1989 (Donnelly et al., , 1994 Donnelly and Findlay, 1994) . Based on amino acid conservation and variation, a generalized TM helix arrangement in the GPCR and packing procedure has been proposed (Baldwin, 1993 ). An automated packing algorithm in a lattice space resulted in a reasonably good model for BR (4.0 Å r.m.s. deviation for the C α atoms; Taylor et al., 1994) . Using the calculated variability index for identifying the precise boundaries of the TM helices and the optimal helical packing, increased accuracies (2.3 Å r.m.s. deviation for the C α atoms; rhodopsin receptor was also built and found to be consistent
The amino acid identity between these two sequences is 23%. The TM with mutagenesis data (Alkorta and Du, 1994) .
regions for both sequences are highlighted by numbers. For example,
The third approach takes advantage of the recently available residues labeled with '1' are part of TM1, etc. structural data for rhodopsin by electron microscopy map (Schertler et al., 1993; Unger and Schertler, 1995) . Such such a way that potential interactions with NPY were formed information has been used in model building as qualitative with key residues identified by mutagenesis studies. A disulfide constraints in some studies (Baldwin, 1993; Donnelly et al., bond was built between Cys113 in EL1 and Cys198 in EL2. 1994). Most recently, using more quantitative constraints Energy minimizations and constrained molecular dynamics derived from the low resolution electron density and a range (MD) simulations that restrict the motion of the TM domain of mutagenesis data for rhodopsin, Herzyk and Hubbard (1995) were then performed to refine the model. The Discover force derived a unique helix packing structure of rhodopsin by field (Biosym) was used for these calculations. Due to the automated Monte Carlo simulated annealing. When this method lack of additional structural constraints, the first 37 residues was applied to BR, a model with 1.8 Å r.m.s. deviation was (residues 1-37) in the N-terminus and the last 50 residues obtained (Herzyk and Hubbard, 1995) . This rhodopsin model, (residues 335-384) in the C-terminus were omitted from the therefore, is probably the best starting point for the development model. Since there is evidence that the N-terminus of the Y1 of a model of the TM structure of the Y1 receptor.
receptor contributes very little to the peptide ligand binding In this study, the transmembrane domain of the human Y1 affinity (Tamm et al., 1994) and the C-terminus is located on receptor model was built using the simplified model of human the intracellular side, this omission should not significantly rhodopsin derived in the third approach described above affect the predicted binding site model. (Herzyk and Hubbard, 1995) . Unlike BR, rhodopsin is a Docking BIBP3226 in the TM regions of the receptor model member of the GPCR superfamily and shares a higher sequence homology with Y1 in a sequence alignment ( Figure 2 ). As we In general, ligand docking into a receptor model may be achieved by either manual docking or automated docking. For will conclude in this study, rhodopsin as a better template to model the GPCR is strongly supported by pairwise reciprocal many GPCR systems where key ligand-receptor interactions are known, manual docking is widely used (MaloneyHuss and mutations and single point mutation experiments.
To build the Y1 receptor model, the TM region of the Y1 Lybrand, 1992; Underwood et al., 1995) . For example, the cationic amine and catechol of norepinephrine and dopamine receptor was first determined by the TM region of the rhodopsin model. Helix kinks were introduced at positions where proline are known to interact with a conserved aspartic acid in TM3 and two serine residues in TM5 (Strader et al., 1989) . A residues are found in the middle of the helices. Extracellular loops (ELs) were added to the model during the docking reasonable docking conformation of the agonists or related ligands may be obtained by manually placing the ligands in process for NPY, since the conformation of the loops may largely depend on the orientation of the peptide ligand in the the space between the three key residues in the receptor model. When the key interactions between the ligand and the receptor complex. The extracellular loops were arranged in receptor are not known, such as in the case of the neuropeptide Building the Y1-NPY complex Y1 receptor, automated docking may be used to obtain initial A model of NPY was first derived from the crystal structure docking conformations with very few assumptions. The only of avian pancreatic polypeptide (Blundell, 1981) as previously assumption introduced in automated docking is the general reported (Allen et al., 1987) . Structural refinement of the location of the ligand binding site. In addition, automated peptide was carried out using energy minimization. Since the docking allows a more systematic exploration of the binding large size of NPY prohibits a reasonable automated docking, pocket of the receptor by searching for the lowest energy NPY was docked manually using the predicted Y1-BIBP3226 interaction mode. Compared with manual docking, automated complex as a guide. It was assumed that the key residues of docking has been less widely used in the modeling of GPCRthe peptide, Tyr1 and Tyr36, occupy approximately the same ligand complexes.
space as the phenyl hydroxyl and diphenylmethyl groups of In this study, the Monte Carlo simulated annealing algorithm BIBP3226 respectively. Such a positioning of Tyr1 and Tyr36 of Goodsell and Olson (1990) was used for the automated anchoring points resulted in a plausible docking conformation docking of BIBP3226 in the TM domain of the Y1 receptor of NPY in the Y1 receptor model, in which another key NPY model. This method allows flexible docking of a ligand with residue, Arg33, overlaps well with the guanidinium group of the receptor held rigid. Since the receptor structure is likely BIBP3226. Although peptide and non-peptide ligands are to be flexible during the binding of a ligand, a rigid receptor thought to bind in different regions of the tachykinin receptor structure is a limitation of this approach. In this method, the (Strader et al., 1989; Suryanarayana and Kobilka, 1993 ), interaction energy between the ligand and the receptor is overlapping the NPY and BIBP3226 binding sites is a reasoncalculated by van der Waals and electrostatic terms. The atomic able assumption given that BIBP3226 was designed to mimic charge parameters were taken from the Discover force field of the NPY structure (Rudolf et al., 1994) . More importantly, as Biosym. Several specific steps were taken in docking BIBP3226
we will see in the Results and discussion section, the mutain the Y1 receptor model. genesis data presented in this study strongly support this To dock BIBP3226 in the Y1 model, the first step involved assumption. the creation of energy grid maps in a cubic box using five
Once an approximate docking of NPY was obtained, the different probes: atoms C, N, O and H and a proton. In order extracellular loops of Y1 were built. The first extracellular to avoid unnecessary computation in the open areas outside loop was built as a flat span between TM2 and TM3, allowing the receptor and the intracellular regions, a 30 Å cubic box NPY to occupy the space above. To build the longer second was assigned to cover the extracellular half of the helix bundle extracellular loop, a disulfide bond between Cys113 and as well as the extracellular loops. This cubic box surrounds Cys198 was first made. A disulfide bond between residues at the generally accepted non-peptide binding site for peptide these two conserved positions has been reported for rhodopsin receptors such as the tachykinins (Fong et al., 1993; Gether (Karnik et al., 1988) and is thought to exist in all GPCRs. et al., 1995; Yamano et al., 1995) , assuming that BIBP3226 Since Cys113 is close to the extracellular end of TM3, the binds to the Y1 receptor in a similar region. The center of the position of Cys113 is relatively well defined and serves as an box was chosen at a point near Cys305 in TM7 so that the anchor point of Cys198. The conformation of EL2 was also cubic box includes the desired region of the receptor. The grid constrained by the NPY peptide docked in the Y1 receptor size of the box was 0.5 Å. To eliminate false cavities outside model, since residues in the loop should not overlap with the helix bundle or beyond the extracellular loops further, a NPY. In addition, key residues important for agonist binding, water solvent shell was created around the receptor model. including Asp190, Asp194 and Asp200, were arranged to form The presence of the water molecules, especially those potential interactions with different residues of NPY. The third surrounding the TM helices, is not expected to affect the extracellular loop is short and was built by simply connecting interaction energy between the ligand and the receptor, since TM6 and TM7. Finally, the intracellular loops were also built no partial charges were assigned to them.
by connecting the corresponding TM regions. The details of Second, to determine the optimal set of docking parameters, the intracellular loop conformations may not be important the temperature reduction factor and the number of simulation since they are distant from the ligand binding sites. steps at each temperature were changed systematically. It was To refine the Y1-NPY model, a stepwise energy minimizafound that when the temperature reduction factor is 0.8 and tion and MD simulations were performed. First, all residues the number of steps at each temperature is 4000, the simulation of NPY and part of the Y1 receptor were fixed while optimizing converges with a reasonably low final energy. To test the EL1 and EL2 by using steepest descent energy minimization convergence of the docking results further, the docking compufollowed by 1100 steps of MD simulations at a constant tation with the optimal parameters was repeated in 10 independtemperature of 300 K. The MD simulations allow the amino ent runs. Each run started at a random initial orientation of acids in the two loop regions to equilibrate and to reach the ligand placed near the center of the grid box. Four of conformations of lower energy minima. The last conformation the 10 runs resulted in similar docking conformations with of the MD simulations was then obtained by energy minimizalow energy. tion using the conjugate gradient method. Second, the complete In the third step, the initial docking conformations generated Y1 receptor-NPY model was refined using energy miniby automated docking were carefully compared with mutamization without constraints to an energy gradient of 1.0 genesis data for BIBP3226 at the Y1 receptor. Small adjustkcal/mol.Å. Some of the side chains of NPY were slightly ments of the diphenylmethyl and hydroxyphenyl groups of adjusted to avoid close contact with the receptor residues BIBP3226 were introduced to bring the antagonist within the before minimization. The distance from each residue of the interaction distance of key residues such as Tyr47 and Phe173.
Y1 receptor to NPY was calculated by locating the closest Structure refinement with energy minimization was then carried out for the model Y1-BIBP3226 complexes.
atom from the residue to the closest atom of the ligand.
TM2, TM3 with TM4 and TM5 with TM6 were also included in the model. The TM helical arrangement proposed in the Y1 receptor model is supported by several interhelical interactions identified through mutagenesis studies (Figure 3a and b) . First, a residue pair, Asp86 of TM2 and Asn316 of TM7, lie adjacent to each other in the model. A direct interaction between these two residues has also been proposed in the GnRH receptor (Zhou et al., 1994) . It was found that, while single mutants resulted in a loss of activity, the reciprocal mutation of these two residues restored activity. Asp86 is a conserved residue in the GPCR superfamily and has been proposed to be involved in sodium binding, an important event for receptor activation (Wang et al., 1991) . The distance between Asp86 and Asn316 in the Y1 receptor model allows a direct interaction between these two residues. On the other hand, an Na ϩ cation could also mediate the interaction between these two residues.
Second, in a recent study of muscarinic receptors (Liu et al. 1995) , M2-M5 chimeras with hybrid TM1 and TM7 were constructed and found to destroy ligand binding. The function highlighted. D86 of TM2 may interact directly with N316 of TM7 in the of M5, the function of the chimera was restored. These results corresponding residues of the GnRH receptor (Zhou et al., 1994) or via an Na ϩ bridge. The interaction between Y47 of TM1 and L303 of TM7 has strongly suggest that these two residues from TM1 and TM7 been observed in the muscarinic receptors (Liu et al., 1995) . In the α 1a and directly interact with each other in the helix bundle. these two residues in the M2 and M5 receptors are Tyr47 in TM1 and Leu303 in TM7 (Figure 3a and b) . These two residues directly interact with each other through hydrophobic contact in the model. The Tyr47-Leu303 residue pair is located Results and discussion near the extracellular end of the helix bundle with Tyr47 The human Y1 receptor model: experimental support for pointing into the interior of the receptor and Leu303 positioned the model between the two helices. In addition, the interaction between The TM domain of the human Y1 receptor model was built TM1 and TM7 has also been studied for the β 2 adrenergic using a simplified model of human rhodopsin derived from an receptor and Asn312 in TM7 was identified to be involved in extensive set of experimental data (Herzyk and Hubbard, 1995) such an interaction (Surayanarayana and Kobilka, 1993) . This as a template. In the model, the seven TM helices of Y1 are residue corresponds to His306 in the Y1 receptor, which is arranged sequentially and counter-clockwise when the receptor near Tyr47 and Phe96 in TM1 (not shown in Figure 3a and b). is viewed from the extracellular side (Figure 3a ). TM3 and Third, two residues in the α 1b adrenergic receptor, Ala204 TM7 are packed towards the center of the TM helix bundle in TM5 and L314 in TM6, were proposed to interact directly and TM1 and TM4 are mostly exposed to the lipid bilayer.
with each other based on the cooperative behavior of their Due to the lack of structural constraints, the first 37 residues mutants in affecting the same structural fragment of the ligands (residues 1-37) in the N-terminus and the last 50 residues (Hwa et al., 1995) . These two residues also contribute to (residues 335-384) in the C-terminus were not built into the subtype selectivity between the α 1b and α 1a receptors. In the model. These omissions should not prevent us from using the Y1 receptor model, these two residues correspond to Thr212 model in identifying ligand binding sites, as mutation and and Asn283, which are within contact distance of each other. chimera data have shown that the N-terminus of the Y1
The above experimental results strongly support the specific receptor contributes very little to peptide ligand binding affinity packing arrangement of the TM helices in the current receptor (Tamm et al., 1994) and the C-terminus is likewise not thought model. It is worth noting that the TM helices are arranged in to play a significant role in ligand binding affinity due to its a sequential and counter-clockwise manner when it is viewed position on the intracellular side of the membrane bilayer.
from the extracellular side. Alternative TM helical arrangeThe extracellular and intracellular loops were also built into ments, such as non-sequential packing of the seven helices by the Y1 receptor model (Figure 3a and b) . The first extracellular exchanging TM1 and TM2 (Zhang and Weinstein, 1993) and loop (EL1) forms a flat span between the ends of TM2 and clockwise packing (MaloneyHuss and Lybrand, 1992) , have TM3 with the disulfide bond forming Cys113 located at the been proposed in the literature. In those arrangements, the end of this loop close to the extracellular end of TM3. The direct interactions between some or all of the residue pairs longer EL2 is arranged toward the top of the model, so that a discussed would not be possible without significantly changing potential interaction between some residues of this loop with the helix orientationos relative to the lipid bilayer. Such a NPY may be formed (see the discussions below). Cys198, the change would result in key residues for ligand binding facing disulfide bond partner with Cys113, is located in the middle the outside of the helix bundle. Another property of the current model supported by experiment is the vertical alignment of of EL2. The three intracellular loops connecting TM1 with Y1 receptor, an orientation that is different from a previously proposed Y1-NPY complex, in which the α-helix of NPY is parallel to the TM helix bundle of Y1 (P. Walker et al., 1994) . In that orientation, it would not be possible to bind the C-terminus of NPY in the deeper pocket.
The Y1-NPY docking conformation is supported by the available structure-activity relationship data for NPY, the Y1 receptor and other GPCRs. An alanine scan of the entire NPY peptide shows that Arg33, Arg35 and Tyr36 are the most important residues for binding with the binding affinity (IC 50 ) decreased by up to 10 4 -fold upon their substitution (Beck-Sickinger and Jung, 1995) . In addition, peptide fragment NPY2-26 (lacking Tyr1) loses its binding affinity for the Y1 receptor by 100-fold, indicating a role of Tyr1 in binding or in maintaining the active conformation of the peptide A.Branchek, the TM helices. In the Y1 receptor models derived from R.L.Weinshank and C.Gluchowski, in preparation). Briefly, bacteriorhodopsin, however, TM7 is shifted towards the individual receptor mutants altered at any one of 14 resiude intracellular side resulting in Leu303 lying~6 Å below Tyr47 (Asp86, Tyr100, Asp104, Trp106, Glu110, Cys113, Gln120, (unpublished results). A direct interaction between these two Asp190, Gln219, Phe221, Phe282, Asn283, Asp287 and residues is impossible in such a alignment.
His306) exhibited a decrease by more than 85% in specific In summary, mutagenesis data from different GPCR systems 125 I-PYY binding relative to the wild type receptors analyzed strongly support the helical arrangement for TM1, TM2, TM5, under the same conditions (Table I ). The dramatically reduced TM6 and TM7 in the Y1 model. The consistency between 125 I-PYY binding signal suggests the importance of the targeted mutagenesis data from different receptor families with the residues for agonist binding. In addition, Asp194 and Asp200 model suggests that the GPCR superfamily shares a similar 3-in EL2 were reported to be critical for agonist binding in the D backbone structure in the TM domain. This is a reasonable Y1 receptor (M.W. Walker et al., 1994; P.Walker et al., 1994) . conclusion, since 3-D structures are much more conserved Thus, there are 16 residues that are important for Y1 receptor than primary sequences within protein families in general. It agonist binding altogether. should be pointed out, however, that, to validate further the NPY and the Y1 receptor interact through a large contact structure of the Y1 model, particularly regions involving surface area in the model. As shown in Figure 5 , there are 73 TM3 and TM4, additional experimental data for interhelical residues within 5 Å of NPY in the model complex. These interactions are necessary.
residues are located in the extracellular loops and part of the The Y1-NPY complex and agonist binding site TM helices near the extracellular end. Comparing with the residues important for agonist binding identified by mutagenAs shown in Figure 4 (a) and (b), the α-helix of NPY was predicted to lie approximately perpendicular to the TM helices esis studies, 12 of these residues are confirmed as key residues for agonist binding, as shown in Table I . Among these residues, of the Y1 receptor with the C-terminus of NPY anchored into the TM bundle. As a result, the C-terminal fragment Arg33-Gln120, Gln219, Asn283 and His306 are located in the transmembrane region in which BIBP3226 binds (see below), Tyr36 of NPY forms an intimate interaction with the transmembrane regions of the Y1 receptor, while the N-terminal residue suggesting an overlap between the agonist and antagonist binding sites. Tyr1 of NPY makes contact with the extracellular regions of the TM bundle and EL1. The regions of NPY adjacent to the Several key residues important for agonist binding in the Y1 receptor are in the same position as known key residues C-and N-termini are surrounded by EL1 and EL2, forming a relatively large contacting surface area between the peptide of other GPCR families. Gln120 corresponds to Asp113 of the β 2 adrenergic receptor, a residue that is known to be important and the receptor. The reverse turn in the middle of the peptide extends outside the receptor with potential contacts with the for receptor recognition in the biogenic amine receptors. In addition, Gln219 is at the position of Ser207 in the β 2 lipid bilayer, which is not included in the model.
The NPY binding site at the Y1 receptor includes the adrenergic receptor, a residue believed to be involved in receptor activation by interacting with one of the hydroxyl extracellular end of the TM helix bundle, where the C-terminus of NPY presumably binds (Figure 4a and b) . The C-terminal groups of norepinephrine (Strader et al., 1989) . The importance of Gln219 and its close proximity to NPY suggests that there tetrapeptide Arg33-Gln34-Arg35-Tyr36 is buried inside the TM helical bundle, consistent with the binding pocket size of is at least one common agonist binding residue and perhaps a common activation mechanism between the biogenic amine a peptide receptor estimated by fluorescence studies (Sklar et al., 1990) . The C-terminus fragment binds in a deeper pocket and Y1 receptors. Given the common evolutionary origin of the members of the GPCR superfamily, such a similarity is surrounded by TM3, TM5, TM6 and TM7. The N-terminus of NPY binds in a shallow pocket near TM1, TM2 and EL1. The not surprising. Peptide GPCRs have also been found to have important α-helix of NPY is nearly perpendicular to the TM helices of the Strader et al. (1989) and Suryanarayana and Kobilka (1993) . e Mouillac et al. (1995) . f Yamano et al. (1992) . g Jernagin et al. (1994) . h Kaupmann et al. (1995) . i The residue numbers of other GPCRs in corresponding positions of a particular key residue of the Y1 receptor are determined by a multiple sequence alignment of the GPCR superfamily (alignment not shown).
receptors. The importance of Phe286 is supported by residue Asp263 of the angiotensin AT 1a receptor. Three key residues in the TM regions of the Y1 receptor, Asp86 in TM2, Phe221 in TM5 and Phe282 in TM6, are relatively distant from NPY in the model complex. Asp86 is a conserved aspartic acid in TM2 and is proposed to be critical for the agonist-induced conformational change of GPCRs (Wang et al., 1991) . Its role in ligand binding may not be direct. Phe221 is on the opposite side of Gln219 in TM5 while Phe282 is in the middle of TM6 with its side chain positioned between two leucine residues of TM7. It is likely that the roles of Phe221 and Phe282 are to maintain the specific packing structure of the TM helices. These residues may be involved in agonist binding indirectly, as it is impossible to rotate TM5 and TM6 so that both these and other key residues face the inside of the bundle while preserving the helix packing Another residue that may affect agonist binding through indirect structural change is Cys113. This residue is one of the two highly conserved cysteines that may form a disulfide residues at the same positions of the Y1 agonist binding bond. Mutation of Cys113 to serine results in the loss of this residues (Table I ). Asp104 of Y1 corresponds to Asn96 of the disulfide bond and thus binding of the agonist. tachykinin receptor NK1. Corresponding to Asn283 of Y1 are key residues found in the somatostatin, bradykinin and NK1
A detailed analysis of the distribution of the 12 key be in different positions in the two docking orientations. In the first orientation, the hydroxyphenyl group points toward TM1, TM2 and TM7 and the guanidinium group faces the extracellular loops near TM6. In the second orientation, the positions of these two functional groups are reversed. For clarity only orientation 1 was shown in Figures 7a and b . A more detailed view of the two docking orientations can be seen in Figure 8 . In orientation 1, the guanidinium group binds near Asp287, a residue which is crucial for agonist binding and which is also proposed to interact with the cationic side chain of Arg33 of NPY ( Figure 6 ). It may thus be postulated that the guanidinium group of BIBP3226 mimics Arg33 in function in the first orientation (Figure 8 ). Conversely, in the second orientation, the guanidinium group binds near 8). Since Tyr100 is proposed to interact with Arg35 of NPY in the agonist docking model through a cation-π interaction (Figure 6 ), the guanidinium group may alternatively be a residues for agonist binding supported by both modeling and mimic for Arg35 function. More detailed investigations with mutagenesis studies shows that several specific interactions complementary ligand and receptor modifications are necessary may be formed ( Figure 6 ). Gln219 is in a position for to choose the most likely binding orientation between the hydrogen bond formation with Tyr36 of NPY. Since this above two scenarios. However, a stronger ion pair interaction residue corresponds to Ser217 of the β 2 adrenergic receptor suggests that orientation 1 is preferred. as discussed above, this hydrogen bond may also be critical There are 32 residues within 5 Å of BIBP3226 in the for receptor activation in the Y1 system. Gln120 may form a orientation 1 model Y1-BIBP3226 complex ( Figure 5 ). As hydrogen bond with the terminal amide group of Tyr36. expected, most of these residues are located in the TM regions, Asp287 may potentially form a salt bridge with Arg33 of although a few are on the border with extracellular loops. NPY. Tyr100 stacks with the guanidinium group of Arg35 and Mutagenesis studies have shown that, when mutated, 11 Y1 the aromatic ring of Tyr1 of NPY, forming cation-π and π-π receptor residues reduce the BIBP3226 binding by more than interactions respectively. In addition, anionic residues, includfive-fold (Table I) . These residues include Tyr47, Gln120, ing Glu110, Asp104, Asp190, Asp194 and Asp200, interact Phe173, Tyr211, Trp276, Phe282, Asn283, Phe286, His298, favorably with various parts of the NPY structure, in which Phe302 and His306. Ten of these residues are within contact positively charged arginine and lysine residues in NPY are distances of the antagonist in the model. One key residue, found (not shown in Figure 6 ).
Phe282, is slightly longer in distance to BIBP3226 (~6 Å).
The Y1-BIBP3226 complex and antagonist binding site
When mutated to alanine, Phe282 is found to affect both the agonist and antagonist binding. The side chain of Phe282 In the Y1-BIBP3226 model complex, the antagonist lies in packs against TM6 and is likely to play an important role in the TM helix bundle near the extracellular end, as shown in helix packing. Figures 7a and b . Two plausible orientations of the antagonist Many Y1 receptor antagonist binding residues are in the were found. Common to both orientations is that the same position of key residues of other peptide and biogenic diphenylmethyl group is buried in a deeper pocket within the amine receptors (Table I) . Specifically, Gln120, Asn283, four helix bundle formed by TM3, TM5, TM6 and TM7. The hydroxyphenyl and the guanidinium groups were predicted to Phe286, Phe302 and His306, residues also important for NPY binding, are supported by data from β 2 adrenergic B 2 , NK1, hydroxyl phenyl in orientation 1. In the less probable orienta-SS1 and V1a receptors. This overlap indirectly supports the tion 2, the positions of the guanidinium and hydroxyphenyl antagonist binding site identified for the Y1 receptor.
groups are reversed, resulting in a loss of a salt bridge between Figure 8 displays the 10 residues that are found to be the guanidinium group and Asp287. In addition, His306, important for antagonist binding based on mutagenesis data Asn283 and Tyr211 may form various hydrogen bonds with as well as three key residues for agonist binding Tyr100, the amide groups of BIBP3226. Gln219 and Asp287. The effect of these agonist binding Recently, another study of the BIBP3226 binding site at the residues on antagonist binding is not known, because critical Y1 receptor was published (Sautel et al., 1996) . The authors residues for agonist binding diminished the agonist binding used a different strategy for ligand docking and for selecting signal. To address this question, binding studies of radiolabeled the residues for mutation, resulting in a slightly different Y1-antagonists, such as 3 H-BIBP3226, are necessary. Nevertheless, BIBP3226 model. However, as in this study, Asp287 of TM6 including some of these residues in the discussion is useful in was proposed to interact with the guanidinium group of the forming hypotheses for receptor recognition and activation ligand. Other key residues, including Phe173, Tyr211, Gln219, and for suggesting further experiments to test these hypotheses.
Asn283 and Phe286 were also found to be important for Several specific interactions may be identified between antagonist binding. BIBP3226 and Y1 (Figure 8 ). The hydroxyphenyl group forms In summary, the binding of BIBP3226 to the Y1 receptor aromatic interactions with Tyr47 and potentially with Tyr100 appears to involve several interaction sites with both hydroof the Y1 receptor. The diphenylmethyl group is surrounded phobic and polar residues. A knowledge of these interaction by Phe173, Trp276 and Tyr211, aromatic residues that form sites may be important for the design of novel Y1 antagonists part of the deeper lipophilic pocket. This pocket is also without peptide character, by replacing the amide peptide proposed to bind Tyr36 of NPY in the Y1-NPY complex.
bonds of BIBP3226 with other spacers that are potentially The absence of a hydrogen bond forming group at the more stable under physiological conditions. In addition, several diphenylmethyl moiety is consistent with the antagonist nature key residues for antagonist binding are not conserved between of BIBP3226 and the speculation that the hydrogen bond the Y1, Y2, Y4 and Y5 subtypes. The positions of these interaction between Tyr36 and Gln219 triggers the receptor divergent residues in the model provide potential sites for activation. Another potential cause of the inhibition of the modifying the ligand to design ligands which are selective for receptor activation by BIBP3226 is the large size of the other NPY receptor subtypes. diphenylmethyl group that may prevent the receptor from Conclusions achieving the conformational change required for function.
Models of the human Y1 receptor and its complexes with These hypotheses can be directly tested by the functional assay peptide agonist NPY and small molecule antagonist BIBP3226 of BIBP3226 analogs with smaller substituents, such as benzyl have been generated. The transmembrane helix packing or analogs with a hydroxyl substituent at various positions of arrangement in the proposed model is supported by mutagenesis the diphenylmethyl moiety. Conversely, the NPY peptide may data. Specifically, three residue pairs that are suggested to be modified with bulkier groups or by removing the hydroxyl form interhelical interactions in different GPCR systems are group, such as amidated phenylalanine and amidated diphenylfound to be adjacent to each other in the model. ethylalanine, at the position of Tyr36. The synthesis of these
The predicted agonist binding site of the Y1 receptor extends compounds is under way. It would be interesting to determine over a relatively large region of the receptor, including almost whether these two classes of modifications will produce nonthe entire EL1, much of EL2 and EL3 and portions of the TM peptide agonists and peptide antagonists at the Y1 receptor.
helices near the extracellular end. The antagonist binding site Other key residues for antagonist binding may also form is mainly localized in the TM regions near the extracellular favorable interactions with BIBP3226. Two aromatic residues, end, overlapping with the agonist binding site. This overlap Phe286 and Phe302, are near the guanidinium group in between the peptide agonist and non-peptide antagonist binding orientation 1, forming cation-π interactions, further stabilizing the binding of this group with Asp287. Phe100 stacks with sites is in contrast to tachykinin receptors, where distinct
